- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
DAPA-CKD Trial Findings Could Transform CKD Therapy
AHA: DAPD-CKD investigator Prof John McMurray talks to Patient Care about the “revolutionary” findings he will highlight at the AHA sessions on opening day.
The Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD) study assessed the effects of dapagliflozin on chronic kidney disease (CKD) in patients with and without type 2 diabetes. The results showed that the SGLT2 inhibitor reduced the study's primary end point (progressive decline in renal function or death from kidney disease) by 39%—with reductions of 36% in patients with diabetes--and 50% in patients without diabetes.
Professor John McMurray, Professor of Cardiology at the University of Glasgow Institute of Cardiovascular & Medical Sciences and one of the lead DAPA-CKD investigators spoke with Patient Care today about the findings and described them as "revolutionary." Professor McMurray will present will the study's findings at the virtual American Heart Association 2020 Scientific Sessions during a featured session on Friday, November 13, 2020.
DAPA-CKD results were published on October 8, 2020, in the New England Journal of Medicine.
